AIM ImmunoTech Inc is trading 86.5% down today at $0.37 following a sharp decline triggered by a heavily dilutive equity and warrant financing package.
- The financing was undertaken to regain or maintain compliance with NYSE American listing standards.
- Despite the significant pressure on the share price, there have been no negative changes to the company's underlying clinical programs.